A mechanism that reduces regulatory T cells (Tregs) during islet autoimmunity onset in Type 1 diabetic patients has been identified, reveals a new study.
Type 1 diabetes is the most common metabolic disease in childhood and adolescence. In this disease, the body's own immune system attacks and destroys the insulin-producing cells of the pancreas.
T-cell Regulator Key to Fight Organ Rejection and Autoimmunity
Transcription factor IRF4 should be the target to solve the problem of transplant rejection or to develop an autoimmunity cure.
Advertisement
‘Developing new and innovative drugs that target miRNA181a and NFAT5 can limit islet autoimmunity.’
Tweet it Now
Regulatory T cells (Tregs) play an important role in this process: In healthy people, they suppress excessive immune reactions and thus prevent autoimmune diseases.
Dr. Carolin Daniel's team is investigating why Tregs fail to protect the islet cells in type 1 diabetes. She is a group leader at the Institute for Diabetes Research (IDF) of Helmholtz Zentrum München and a scientist in the DZD.
![Researchers Identify Proteins Linked to Autoimmunity]( "Researchers Identify Proteins Linked to Autoimmunity")
Researchers at Walter and Eliza Hall Institute in Australia have identified two proteins that play an important role in autoimmunity.
In the current study, she and her team elucidated a mechanism that causes fewer Tregs to be produced during islet autoimmunity onset and that therefore allows the immune system to get out of control and attack.
According to the findings of the study, miRNA181a and NFAT5 molecules play a key role. "We showed that miRNA181a leads to the activation of the transcription factor NFAT5 during islet autoimmunity onset," said Daniel. "The consequence is an inhibition of Treg induction and thus increased immune activation."
Axis pharmacologically interrupted
In order to test the suitability of this new finding for possible therapeutic approaches, the scientists led by the first author Isabelle Serr investigated a preclinical model with early-stage islet autoimmunity.
If the researchers interrupted the miRNA181a/NFAT5-axis, they observed a significantly lower activation of the immune system and an increased formation of Tregs. This was achieved both by the pharmacological inhibition of miRNA181a as well as of NFAT5.
"The targeted inhibition of miRNA181a or NFAT5 could open up new approaches to reduce the activity of the immune system against its own islet cells," said Professor Anette-Gabriele Ziegler, director of the IDF.
"The combination with other immune modulating therapeutic approaches would also be conceivable as an intervention."
In the future, the scientists want to further investigate these findings in preclinical tests.
To this end, humanized models will be used to test whether the combination of insulin vaccination and inhibition of the miRNA181a/NFAT5 axis leads to a more tolerant immune system towards insulin-producing cells.
Source: Eurekalert
Researchers Identify Proteins Linked to Autoimmunity
Researchers at Walter and Eliza Hall Institute in Australia have identified two proteins that play an important role in autoimmunity.
Advertisement
In the current study, she and her team elucidated a mechanism that causes fewer Tregs to be produced during islet autoimmunity onset and that therefore allows the immune system to get out of control and attack.
According to the findings of the study, miRNA181a and NFAT5 molecules play a key role. "We showed that miRNA181a leads to the activation of the transcription factor NFAT5 during islet autoimmunity onset," said Daniel. "The consequence is an inhibition of Treg induction and thus increased immune activation."
Axis pharmacologically interrupted
In order to test the suitability of this new finding for possible therapeutic approaches, the scientists led by the first author Isabelle Serr investigated a preclinical model with early-stage islet autoimmunity.
If the researchers interrupted the miRNA181a/NFAT5-axis, they observed a significantly lower activation of the immune system and an increased formation of Tregs. This was achieved both by the pharmacological inhibition of miRNA181a as well as of NFAT5.
"The targeted inhibition of miRNA181a or NFAT5 could open up new approaches to reduce the activity of the immune system against its own islet cells," said Professor Anette-Gabriele Ziegler, director of the IDF.
"The combination with other immune modulating therapeutic approaches would also be conceivable as an intervention."
In the future, the scientists want to further investigate these findings in preclinical tests.
To this end, humanized models will be used to test whether the combination of insulin vaccination and inhibition of the miRNA181a/NFAT5 axis leads to a more tolerant immune system towards insulin-producing cells.
Source: Eurekalert
Research Defines Molecular On-off Switches for Cancer and Autoimmunity
Scientists from the Institute for Advanced Studies in New Jersey are examining how oncogenes and tumour suppressor genes handle cellular stress, and said that each of these opposing
Advertisement
 Autoimmunity may be the Cause of the Mysterious Nerve Damaging DisorderImmunoglobulin infusions improve pain and function in 75 percent of patients thought to have autoimmune small-fiber polyneuropathy. | Advertisement
|
Advertisement
Recommended Reading
Latest Diabetes News
The US Food and Drug Administration (FDA) clears the 'bionic pancreas' that improves the management of type 1 diabetes, without the need for constant blood sugar testing.
A new study investigated the use of a mathematical model of glucose metabolism to assess continuous glucose monitor data as a metric of dysfunctional glycemic control.
At least 400 medicinal plants effective in decreasing sugar levels in the blood which is critical to control type 2 diabetes identified.
Considering the enormous type 2 diabetes patient population in China, a new oral insulin therapy will improve treatment.
The use of biodegradable “nanoscavengers” to restore insulin sensitivity and treat type 2 diabetes has been discovered.